期刊文献+

替吉奥胶囊联合奥沙利铂治疗老年晚期食管癌疗效观察 被引量:8

Efficiency of combination chemotherapy with S-1 and Oxaliplantin in the treatment of old advanced esophageal cancer patients
下载PDF
导出
摘要 目的观察替吉奥胶囊联合奥沙利铂治疗老年晚期食管癌的临床疗效和不良反应。方法 63例晚期食管癌患者,年龄均>65岁,采用替吉奥胶囊联合奥沙利铂方案治疗,21 d为一周期,治疗2个周期后评价疗效及不良反应。结果 63例患者中CR 8例,PR 23例,SD 14例,PD 18例,有效率RR为49.2%,中位生存时间10.4个月。毒副反应主要为感觉神经毒性、消化道反应和血液学毒性。结论替吉奥胶囊联合奥沙利铂治疗老年晚期食管癌疗效较好,不良反应轻,患者耐受性好,值得临床推广应用。 Objective To observe the efficacy and side effects of S-1 and oxaliplantin in the treatment of old advanced esophageal cancer patients. Methods 63 cases of advanced esophageal cancer, all were older than 65, treated with S-1 and oxaliplantin, the cycle was repeated every 21 days, after two consecutive treatment, the short term efficacy and adverse effects was observed. Results Among the 63 patients, 8 paients were CR, 23 patients PR, 14 SD, 18 PD, the overall response rate was 49. 2%, the middle survival time was 10.4 months. Major side-effects were neurosensory toxicity, gastrointestinal disturbance, and hematological toxicities. Conclusion S-1 and Oxaliplantin is effective for the old advanced esophageal cancer patients, and the toxicity and side-effects are tolerable.
作者 郑慧 马保庆
机构地区 安阳市肿瘤医院
出处 《中国现代药物应用》 2014年第5期9-10,共2页 Chinese Journal of Modern Drug Application
关键词 食管癌 替吉奥 奥沙利铂 化疗 S-1 Esophageal cancer Oxaliplantin Chemotherapy
  • 相关文献

参考文献9

二级参考文献28

  • 1郭颖英,方伟虹,谢淑萍.替吉奥联合奥沙利铂治疗进展期胃癌疗效观察[J].浙江中医药大学学报,2010,34(5):783-783. 被引量:22
  • 2Ikeda K,Yoshisue K,Matsushima E,et al.Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro[J].Clin Cancer Res,2000,6:4409.
  • 3Horio T,Tsujimoto H,Akase T,et al.Syndrome of inappropriate antidiuretic hormone secretion following adjuvant CDDP and 5-FU administration in a patient with esophageal carcinoma[J].Gan To Kagaku Ryoho,2010,37(10):1945.
  • 4Rudholm T,Wallin B,Theodorsson E,et al.Release of regulatory gut peptides somatostatin,neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats[J].Regul Pept,2009,152(1-3):8.
  • 5Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0 : development of a comprehensive grading system for the adverse effects of cancer treatment [ J]. Semin Radiat Oncol,2003 ; 13 ( 3 ) : 176-81.
  • 6Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil,in advanced gastric cancer [ J ]. Oneology,2000 ;58 (3) :191-7.
  • 7Jin ML,Lu HS,Li J,et al. Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP ( SP ) versus 5-FU/CDDP ( FP ) in patients (pts) with advanced gastric cancer ( AGC ) : SC -101 study [ J ]. Proc ASCO ,2008 ;26:221.
  • 8Koizumi W, Narahara H, Hara T,et al. S-1 plus cisplatin alone versus S-1 alone for first line treatment of advanced gastric cancer ( SPIRITS trial : a Phase Ⅲ tiral ) [ J ]. Lancet Oncol,2008 ; 9:215.
  • 9Kang Y,Kang WK,Shin DB,et al. Randomized phase Ⅲ trial of capecitabine / cisplatin vs continuous infusion of 5-FU / cisplatin as first line therapy in patients with advanced gastric cancer:efficacy and safety results[J]. Proc Am Soc Clin Oncol,2006;24:183.
  • 10Li X M,Arch Toxicol,1998年,72卷,9期,574页

共引文献431

同被引文献82

  • 1勒世联.不同化疗方案一线治疗老年晚期胃癌的近期疗效分析[J].中国生化药物杂志,2014,34(1):108-110. 被引量:9
  • 2葛乃建,李苏宜.食管癌内科治疗研究新进展[J].东南大学学报(医学版),2007,26(3):237-240. 被引量:10
  • 3Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0 : development of a comprehensive grading system for the adverse effects of cancer treatment [ J ]. Semin Radiat Oneo1,2003,13 ( 3 ) : 176 : 181.
  • 4Fujitani K. Overview of adjuvant and neoadjuvant therapy for resect- able gastric cancer in the East[J]. Dig Surg,.2013,30(2) :119 -129.
  • 5Torre L A,Bray F,Siegel R L,et al. Global cancer statistics, 2012 [J]. CA~A Cancer Journal for Clinicians,2015,65(2) : 87-108.
  • 6Chen W,Zheng R,Baade PD,et al. Cancer statistics in China, 2015 [J]. CA:A Cancer Journal for Clinicians,2016,66(2) : 115-132.
  • 7van Meerten E,Eskens FA,van Gameren EC,et al. First- line treatment with oxaliplatin and capecitabine in pa- tients with advanced or metastatic oesophageal caneer:a phase II study [J]. Br J Cancer,2007,96(9) :1348-1352.
  • 8Koizumi W, Boku N,Yamaguchi K, et al. Phase II study of S-1 plus leuc0vorin in patiefits with metastatic eolorectal cancer [J]. Annals of Oncology, 2010,21 (4) :766-771.
  • 9Kawa'hara M. Efficacy of S-1 in. non-small cell tung can- cer [J]. Expert Opin Pharmaeother, 2014,15 (13):1927- 1942.
  • 10Akutsu Y,Kono T,Uesato M,et al. S-1 monotherapy as sec- ond-or third-line chemotherapy for. unresectable and~recur- rent esophageal squamous cell earcinoma [J]. Oncology, 2013,84(5) : 305-310.

引证文献8

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部